MAB3404 Sigma-AldrichAnti-Cytokeratin 18 Antibody, clone CK2

Liver regeneration is mainly based on cellular self-renewal including progenitor cells. Efforts have been made to harness this potential for cell transplantation, but shortage of hepatocytes and premature differentiated progenitor cells from extra-hepatic organs are limiting factors. Histological studies implied that resident cells in adult liver can proliferate, have bipotential character and may be a suitable source for cell transplantation.Particular cell populations were isolated after adequate tissue dissociation. Single cell suspensions were purified by Thy-1 positivity selection, characterised in vitro and transplanted in immunodeficient Pfp/Rag2 mice.Thy-1(+) cells that are mainly found in the portal tract and the surrounding parenchyma, were isolated from surgical liver tissue with high yields from specimens with histological signs of regeneration. Thy-1(+) cell populations were positive for progenitor (CD34, c-kit, CK14, M2PK, OV6), biliary (CK19) and hepatic (HepPar1) markers revealing their progenitor as well as hepatic and biliary nature. The potential of Thy-1(+) cells for differentiation in vitro was demonstrated by increased mRNA and protein expression for hepatic (CK18, HepPar1) and biliary (CK7) markers during culture while progenitor markers CK14, chromogranin A and nestin were reduced. After transplantation of Thy-1(+) cells into livers of immunodeficient mice, engraftment was predominantly seen in the periportal portion of the liver lobule. Analysis of in situ material revealed that transplanted cells express human hepatic markers HepPar1 and albumin, indicating functional engraftment.Bipotential progenitor cells from human adult livers can be isolated using Thy-1 and might be a potential candidate for cell treatment in liver diseases.

Anti-SLA antibodies characterize a newly defined subgroup of patients with autoimmune chronic active hepatitis. The aim of the present study was the immunochemical characterization of the target antigen(s) of anti-SLA antibodies. Anti-SLA-positive sera were found to contain high titres of anti-cytokeratin antibodies. In immunoblotting analyses with 100,000 x g supernatants of human liver homogenates (S-100) these sera recognized various proteins with a molecular mass of 40-60 kDa. These proteins were also recognized by monoclonal anti-cytokeratin antibodies. Two-dimensional co-electrophoresis and immunoblotting analysis of S-100 and liver cytokeratins showed that anti-SLA antibodies were primarily directed against cytokeratins, particularly against liver cytokeratin types 8 and 18. This was supported by affinity chromatography, immunofluorescence and absorption methods using anti-SLA sera.

Monoclonal antibody CK2, recognizing component No. 18, appeared to be the most suitable reagent for the detection of epithelial tumor cells in bone marrow. Its specificity was confirmed in a double-marker staining procedure (combination of APAAP-technique and radioautography). CK2 positive cells were demonstrated not to reveal any cross-reactivity with an antibody directed against the "leucocyte common antigen". A significant correlation between the presence of epithelial tumor cells in bone marrow and certain conventional risk factors was found. A more detailed phenotypic characterisation could demonstrate the expression of proliferation associated antigens on these cells. Furthermore in an immunotherapeutic approach with monoclonal antibody 17-1A, labelling of the disseminated tumor cells in bone marrow after infusion of the antibody was shown.

Carcinomas of different origin have been tested in immunofluorescence microscopy with the monoclonal murine antibodies CK1-CK4, which recognize a single cytokeratin polypeptide (human cytokeratin No. 18) present in simple but not in stratified squamous epithelia, and with the monoclonal antibody KG8.13 and guinea pig kerA antibodies, both of which recognize a variety of cytokeratins common to almost all epithelial cell types. Tumors derived from simple epithelia, including adenocarcinomas and some other tumors such as ductal breast carcinomas, were strongly stained by all three antibodies. So was a transitional carcinoma of the bladder. In contrast, basal cell epithelioma, cloacogenic carcinoma, and squamous cell carcinoma of skin, tongue, and esophagus appeared negative with CK1-CK4 but positive with the other two antibodies. Other squamous cell carcinomas derived from epiglottis and cervix uteri showed a mixture of positive and negative cells when tested with CK1-CK4, although all tumor cells were positive when tested with KG8.13 and with kerA. Thus, use of an appropriate collection of cytokeratin antibodies with different specificities not only allows tumors of epithelial origin to be distinguished from other tumor types but, in addition, allows a further subdivision of carcinomas in relation to their histologic origin.

Four monoclonal antibodies designated CK1 - CK4 were obtained from fusions of mouse myeloma F0 cells with spleen cells from BALB/c mice immunized with cytoskeletal preparations made by treatment of human HeLa cells with non-ionic detergents. These IgG1 type antibodies all recognize, in immune blots, cytokeratin 18 (45 kd, pI 5.7) in the catalogue of 19 human cytokeratin species developed by Moll et al. (1982). Immunofluorescence microscopy on human material shows that CK1 - CK4 stain a wide variety of simple epithelia (e.g., intestine, respiratory and urinary systems, liver, glandular epithelia) but do not stain stratified squamous epithelia (e.g., oesophagus, epidermis) or non-epithelial cells. The immunofluorescence results, developed mainly by gel electrophoresis, support the concept of cytokeratin divergence in different epithelia and clarify, for cytokeratin 18, some unsolved problems posed by high tissue complexity. CK2 appears specific for human, CK1 and CK3 for primates, while CK4 shows broad cross-species reactivity. Thus, CK1 - CK4 appear to be valuable tools for cytokeratin typing and initial experiments also suggest that they can be used to further subdivide human tumours of epithelial origin.